Vectus Biosystems Limited engages in the medical research and development activities in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.50|
|52 Week High||AU$0.88|
|52 Week Low||AU$1.89|
|1 Month Change||-3.85%|
|3 Month Change||11.52%|
|1 Year Change||53.06%|
|3 Year Change||114.29%|
|5 Year Change||4.17%|
|Change since IPO||-3.23%|
Recent News & Updates
Our Take On Vectus Biosystems' (ASX:VBS) CEO Salary
The CEO of Vectus Biosystems Limited ( ASX:VBS ) is Karen Duggan, and this article examines the executive's...
|VBS||AU Biotechs||AU Market|
Return vs Industry: VBS exceeded the Australian Biotechs industry which returned -0.6% over the past year.
Return vs Market: VBS exceeded the Australian Market which returned 17.9% over the past year.
Stable Share Price: VBS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: VBS's weekly volatility (10%) has been stable over the past year.
About the Company
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure. Its lead compound is VB0004, which has potent anti-hypertensive properties, as well as anti-fibrotic activity in the heart and kidneys.
Vectus Biosystems Fundamentals Summary
|VBS fundamental statistics|
Is VBS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VBS income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.13|
|Net Profit Margin||-5,248.89%|
How did VBS perform over the long term?See historical performance and comparison
Is Vectus Biosystems undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Vectus Biosystems is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Vectus Biosystems has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is Vectus Biosystems forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Vectus Biosystems has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Vectus Biosystems performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VBS is currently unprofitable.
Growing Profit Margin: VBS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VBS is unprofitable, but has reduced losses over the past 5 years at a rate of 0.3% per year.
Accelerating Growth: Unable to compare VBS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VBS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (45.9%).
Return on Equity
High ROE: VBS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Vectus Biosystems's financial position?
Financial Position Analysis
Short Term Liabilities: VBS has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: VBS has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: VBS has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: VBS's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VBS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VBS has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 3.2% each year.
What is Vectus Biosystems's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VBS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VBS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VBS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VBS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VBS's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. Karen Annette Duggan serves as the Chief Executive Officer of Vectus Biosystems Limited and has been its Executive Director since September 4, 2006. Dr. Duggan is the Founder of Vectus. She was formall...
CEO Compensation Analysis
Compensation vs Market: Karen's total compensation ($USD164.92K) is below average for companies of similar size in the Australian market ($USD300.22K).
Compensation vs Earnings: Karen's compensation has been consistent with company performance over the past year.
Experienced Board: VBS's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 34.7%.
Vectus Biosystems Limited's employee growth, exchange listings and data sources
- Name: Vectus Biosystems Limited
- Ticker: VBS
- Exchange: ASX
- Founded: 2005
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$47.806m
- Shares outstanding: 31.87m
- Website: https://www.vectusbiosystems.com.au
Number of Employees
- Vectus Biosystems Limited
- 3-11 Primrose Avenue
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/14 07:04|
|End of Day Share Price||2021/10/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.